These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34139302)

  • 1. Potential Repositioning of Anti-cancer EGFR Inhibitors in Alzheimer's Disease: Current Perspectives and Challenging Prospects.
    Mansour HM; Fawzy HM; El-Khatib AS; Khattab MM
    Neuroscience; 2021 Aug; 469():191-196. PubMed ID: 34139302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries.
    Tavassoly O; Sato T; Tavassoly I
    Mol Pharmacol; 2020 Jul; 98(1):13-22. PubMed ID: 32350120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer's disease.
    Mansour HM; Fawzy HM; El-Khatib AS; Khattab MM
    Neural Regen Res; 2022 Sep; 17(9):1913-1918. PubMed ID: 35142667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease.
    Lee H; Kim E
    Arch Pharm Res; 2020 Sep; 43(9):932-960. PubMed ID: 32909178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR is a potential dual molecular target for cancer and Alzheimer's disease.
    Choi HJ; Jeong YJ; Kim J; Hoe HS
    Front Pharmacol; 2023; 14():1238639. PubMed ID: 37601068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing autophagy in Alzheimer's disease through drug repositioning.
    Eshraghi M; Ahmadi M; Afshar S; Lorzadeh S; Adlimoghaddam A; Rezvani Jalal N; West R; Dastghaib S; Igder S; Torshizi SRN; Mahmoodzadeh A; Mokarram P; Madrakian T; Albensi BC; Łos MJ; Ghavami S; Pecic S
    Pharmacol Ther; 2022 Sep; 237():108171. PubMed ID: 35304223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug Repositioning for Alzheimer's Disease].
    Ihara M; Saito S
    Brain Nerve; 2019 Sep; 71(9):961-970. PubMed ID: 31506398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients.
    Bayraktar A; Li X; Kim W; Zhang C; Turkez H; Shoaie S; Mardinoglu A
    J Transl Med; 2023 May; 21(1):332. PubMed ID: 37210557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer drugs with high repositioning potential for Alzheimer's disease.
    Majeed J; Sabbagh MN; Kang MH; Lawrence JJ; Pruitt K; Bacus S; Reyna E; Brown M; Decourt B
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):311-332. PubMed ID: 38100555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
    Ihara M; Saito S
    J Alzheimers Dis; 2020; 74(4):1013-1028. PubMed ID: 32144994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-lactam antibiotics to tame down molecular pathways of Alzheimer's disease.
    Kumari S; Deshmukh R
    Eur J Pharmacol; 2021 Mar; 895():173877. PubMed ID: 33453224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.
    Mousa SA; Ayoub BM
    Neural Regen Res; 2019 May; 14(5):745-748. PubMed ID: 30688255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
    Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
    PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease.
    Jojo GM; Kuppusamy G
    J Clin Pharm Ther; 2019 Jun; 44(3):337-348. PubMed ID: 30738020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metal Ions in Alzheimer's Disease: A Key Role or Not?
    Liu Y; Nguyen M; Robert A; Meunier B
    Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interference between SARS-COV-2 and Alzheimer's disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic.
    Mansour HM
    Ageing Res Rev; 2024 Feb; 94():102195. PubMed ID: 38244862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential.
    Angelopoulou E; Piperi C
    Neuromolecular Med; 2019 Sep; 21(3):227-238. PubMed ID: 31313064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.